These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

972 related items for PubMed ID: 3260908

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD.
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [Abstract] [Full Text] [Related]

  • 23. Murine interstitial nephritis. IV. Long-term cultured L3T4+ T cell lines transfer delayed expression of disease as I-A-restricted inducers of the effector T cell repertoire.
    Mann R, Zakheim B, Clayman M, McCafferty E, Michaud L, Neilson EG.
    J Immunol; 1985 Jul; 135(1):286-93. PubMed ID: 2582035
    [Abstract] [Full Text] [Related]

  • 24. Requirements for T cell recognition and elimination of retrovirally-transformed cells.
    Greenberg P, Klarnet J, Kern D, Okuno K, Riddell S, Cheever M.
    Princess Takamatsu Symp; 1988 Jul; 19():287-301. PubMed ID: 2479634
    [Abstract] [Full Text] [Related]

  • 25. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 26. Do L3T4+ T cells act as effector cells in protection against influenza virus infection.
    Lightman S, Cobbold S, Waldmann H, Askonas BA.
    Immunology; 1987 Sep 15; 62(1):139-44. PubMed ID: 2820868
    [Abstract] [Full Text] [Related]

  • 27. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
    Kern DE, Klarnet JP, Jensen MC, Greenberg PD.
    J Immunol; 1986 Jun 01; 136(11):4303-10. PubMed ID: 2422280
    [Abstract] [Full Text] [Related]

  • 28. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY, Chou T, Sakai K.
    J Immunol; 1989 Jul 15; 143(2):740-8. PubMed ID: 2738408
    [Abstract] [Full Text] [Related]

  • 29. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K, Chang AE, Shu S.
    Cell Immunol; 1990 Aug 15; 129(1):241-55. PubMed ID: 2364440
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 32. Adoptive immunotherapy of newly induced murine sarcomas.
    Shu SY, Rosenberg SA.
    Cancer Res; 1985 Apr 15; 45(4):1657-62. PubMed ID: 3872168
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness.
    Mizuochi T, Munitz TI, McCarthy SA, Andrysiak PM, Kung J, Gress RE, Singer A.
    J Immunol; 1986 Nov 01; 137(9):2740-7. PubMed ID: 2944960
    [Abstract] [Full Text] [Related]

  • 35. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 01; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

  • 36. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.
    Greenberg PD, Cheever MA.
    J Biol Response Mod; 1984 Oct 01; 3(5):455-61. PubMed ID: 6239012
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Antibodies to the L3T4 and Lyt-2 molecules interfere with antigen receptor-driven activation of cloned murine T cells.
    Moldwin RL, Havran WL, Nau GJ, Lancki DW, Kim DK, Fitch FW.
    J Immunol; 1987 Aug 01; 139(3):657-64. PubMed ID: 2955046
    [Abstract] [Full Text] [Related]

  • 39. Immunoglobulin-dependent helper T cells: studies in the MOPC-315 system suggest a novel surface antigen phenotype.
    Rohrer JW, Kemp JD.
    J Immunol; 1986 Sep 15; 137(6):1786-92. PubMed ID: 2943802
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.